Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06184464 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostatic Size Reduction Following of Leuprorelin Acetate

Study acronym: PROSTSIZE
StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated December 15, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jul 15, 2024 to Dec 15, 2024v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Apr 15, 2024 to Jul 15, 2024
    • Study completion date: Jul 15, 2024 to Dec 15, 2024
    • Start date changed from estimate of Jan 1, 2024 to Feb 2, 2024
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
Trial Details
NCT Number NCT06184464
Lead Sponsor Consorci Sanitari de Terrassa
Conditions
(from sponsor)		 Prostate Cancer Adenocarcinoma, Prostate Adenocarcinoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov